Can-Fite BioPharma (CANF) Short Interest Ratio & Short Volume

Short interest is the volume of Can-Fite BioPharma shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 77,500 shares of CANF short. 2.19% of Can-Fite BioPharma's shares are currently sold short. Learn More on Can-Fite BioPharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.19% of Can-Fite BioPharma's floating shares are currently sold short.

Can-Fite BioPharma saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 77,500 shares, a decrease of 47.2% from the previous total of 146,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

2.19% of Can-Fite BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Can-Fite BioPharma: Synlogic, Inc. (0.51%), GeoVax Labs Inc. (6.84%), Allarity Therapeutics, Inc. (9.11%), ProPhase Labs, Inc. (1.71%), UNITY Biotechnology, Inc. (5.57%), Edesa Biotech, Inc. (0.25%), VYNE Therapeutics Inc. (2.46%), 23andMe Holding Co. (11.90%), NextCure, Inc. (0.33%), Acurx Pharmaceuticals, Inc. (1.45%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), MicroStrategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling CANF is an investing strategy that aims to generate trading profit from Can-Fite BioPharma as its price is falling. CANF shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Can-Fite BioPharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CANF, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CANF, twice per month. The most recent reporting period available is May, 31 2025.